Last week the markets found its footing after a sharp sell-off in May. Looking at our MS Performance Tracker it appears that tech rebounded marginally more than biotech, and on par with the rest of the healthcare sector.
The Nasdaq gained +5.58% while the XBI (S&P Bio ETF), IBB, and XLV gained +3.09%, +2.74%, and +4.02%, respectfully. The DOWJ and S&P500 closed the week up +4.69% and +4.70%, respectfully. However, when we slide over and look at the 30-day change, we see that healthcare and biotech outperformed all 3 of the major indices. Big pharmaceutical companies performed well overall too. The ones followed by our tracker gained a cumulative 15.06% in the last 30-days while the Nasdaq, DOWJ, and S&P 500 lost a couple percentage points.
I expect healthcare and biotech to continue to outperform the greater markets. On Friday June 7th president Trump tweeted the U.S. would not be hitting Mexico with tariffs on Monday. I expect the markets to be green on Monday and because of this makes it a great opportunity to day-trade.
Shares of Amgen (AMGN) closed up +3.4% on Monday after releasing positive data at the American Society of Clinical Oncology (ASCO). A phase 1 trial evaluating a KRAS G12C inhibitor in patients with Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer (CRC), achieved favorable partial and overall response rates. Mirati Therapeutics (MRTX), which is developing the same class of drug, closed the week up +47% at $99.77. Their data is not due until later in 2019.
La Jolla Pharmaceutical Company (LJPC) had a stellar week running 139% to $12.86. An interim analysis of a phase 2 study in patients with hereditary hemochromatosis (HH) hit its primary endpoint. A full data readout is expected later this year.
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) closed the week up +20% at $67.01 because of buyout rumors.
Motif Bio plc (MTFB) share price tumbled -43% to $1.13 on Thursday. The FDA has requested additional clinical trials for the company’s lead candidate for treating acute bacterial skin and skin structure infections (ABSSSI). MTFB previously received a complete response letter (CRL) in February of this year.
InflaRx (IFRX) had its valuation slashed -91% on news that its phase 2 trial in patients with moderate to severe Hidradenitis Suppurativa (HS) missed its primary endpoint. As a result, ChemoCentryx, Inc. (CCXI), who is developing a similar compound for the same indication, fell -23%. CCXI has phase 2b top-line data expected next year.
Xeris Pharmaceuticals, Inc. (XERS) dropped -22% to $8.51 after the FDA extended the company’s PDUFA 3-months to September. This came on the heels of an information request from the FDA.
My number one clinical stage bio pick ADMA Biologics (ADMA) had a rough week in particular. All-in-all, ADMA’s share price shed -10% of its value closing the week at $3.78. What looked at first to be a knee-jerk reaction to an “investigation into a breach of fiduciary duties by the board of directors”, as discussed by Zion in this article, turned out to be the selling of 4.2 million shares by the Biotest Divestiture Trust. On a positive note, ADMA president and CEO presented at the Jefferies 2019 Investor Healthcare Conference which I covered in this article.
Clinical Stage With A Catalyst
- Achieve Life Sciences (ACHV) $3.64
- Acer Therapeutics (ACER) $16.40
- Priority review PDUFA date on June 25th.
- Very low float (3.5M) making it highly susceptible to volatile swings up, and down.
- Aclaris Therapeutics (ACRS) $4.74
- ArQule (ARQL) $6.51
- Intra-Cellular Therapies (ITCI) $11.34
- AMAG Pharmaceuticals (AMAG) $9.69
- CymaBay Therapeutics (CBAY) $11.51
- Dova Pharmaceuticals (DOVA) $9.05
- Minerva Neurosciences (NERV) $5.21
- Sunesis Pharmaceuticals, Inc (SNSS) $.76
- Krystal Biotech (KRYS) $31.52
- Top-line phase 2 data expected 2Q19.
- Very low float (7.5 M) making it highly susceptible to volatile swings up, and down
- Sesen Bio (SESN) $2.32
- BLA meeting between SESN and FDA happened on June 6th to discuss a BLA (biologics license application) for Vicinium.
- The company is hosting a conference call Monday morning 8 AM EST to discuss the outcome of the meeting.
- Savara Inc (SVRA) $10.13
- Verrica Pharmaceuticals (VRCA)
MS Money Move and its Chief Operating Officer who is a scientist and individual investor, as well as its affiliates are not registered financial advisors. Our posts should serve as educational material to help you conduct due diligence research. Posts and articles are not directives or recommendations to invest in any security. We reserve the right to buy or sell any security for ourselves without any notification except when required by law. We are not responsible for the action of our affiliates. Investment theses may change due to the variable nature of the securities market. Because of this there is great risk when investing in stocks and options which can result is capital loss. Additionally, past performance by MS Money Moves or any security is not a predictor of future performance. Everyone should conduct their own research and due diligence before making an investment decision. We recommend you consult a financial advisor regarding any investment action.
The biotech sector is especially volatile. Stock prices may fluctuate substantially based on material or nonmaterial developments. We encourage everyone to familiarize themselves with clinical trial processes, relevant terminology, FDA/SEC rules and regulations, and the general processes of drug & therapy development/approval. Always do independent research in a security prior to investing.